Omeros (OMER) Cash from Investing Activities (2010 - 2026)
Omeros' (OMER) quarterly Cash from Investing Activities came in at $28.7 million in Q1 2026, down 25.45% year-on-year from $38.5 million in Q1 2025, and down 74.24% quarter-over-quarter from $111.5 million in Q4 2025.
Omeros (OMER) Cash from Investing Activities (2010 - 2026) Analysis & Trends
Omeros has disclosed Cash from Investing Activities across 17 years of filings, most recently posting $28.7 million for Q1 2026.
- Cash from Investing Activities for Q1 2026 came in at $28.7 million, down 25.45% year-over-year; the trailing twelve-month figure through Mar 2026 was $154.7 million (down 15.31% YoY), and the FY2025 annual result was $164.5 million, up 100.11% from the prior year.
- Cash from Investing Activities came in at $28.7 million for Q1 2026 at Omeros, down from $111.5 million in the prior quarter.
- In the past five years, Cash from Investing Activities ranged from a high of $116.2 million in Q4 2023 to a low of -$181.3 million in Q1 2023.
- The 5-year median for Cash from Investing Activities is $33.0 million (2022), against an average of $10.3 million.
- Across the five-year window, Cash from Investing Activities sank 332.87% in 2022 and surged 219.12% in 2025, its largest moves.
- Omeros' Cash from Investing Activities stood at -$108.5 million in 2022, then soared by 207.15% to $116.2 million in 2023, then plunged by 69.93% to $35.0 million in 2024, then soared by 219.12% to $111.5 million in 2025, then sank by 74.24% to $28.7 million in 2026.
- The last three Cash from Investing Activities figures came in at $28.7 million (Q1 2026), $111.5 million (Q4 2025), and -$6.9 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Investing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | -2.89 Mn |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | 638.50 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | -431.90 Mn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | 579,519.10 |
| 10 | Omeros | 737.87 Mn | 602.55 Mn | 9.31 Mn | 28.73 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 28.73 Mn |
| Mar 31, 2026 | 28.73 Mn |
| Dec 31, 2025 | 111.55 Mn |
| Dec 31, 2025 | 111.55 Mn |
| Sep 30, 2025 | -6.86 Mn |
| Sep 30, 2025 | -6.86 Mn |
| Jun 30, 2025 | 21.30 Mn |
| Jun 30, 2025 | 21.30 Mn |
| Mar 31, 2025 | 38.54 Mn |
| Mar 31, 2025 | 38.54 Mn |
| Dec 31, 2024 | 34.95 Mn |
| Dec 31, 2024 | 34.95 Mn |
| Sep 30, 2024 | 36.04 Mn |
| Sep 30, 2024 | 36.04 Mn |
| Jun 30, 2024 | 73.15 Mn |
| Jun 30, 2024 | 73.15 Mn |
| Mar 31, 2024 | -61.93 Mn |
| Mar 31, 2024 | -61.93 Mn |
| Dec 31, 2023 | 116.24 Mn |
| Dec 31, 2023 | 116.24 Mn |